On July 29, 2026, the American Heart Association reported an independent analysis published in the Journal of the American Heart Association that finally put numbers on the 2025 High Blood Pressure guideline: 22.8 million US adults are clearly eligible for blood-pressure-lowering medication, and 9.7 million of them, more than 40%, are not receiving it. Buried in the method is a detail that matters to anyone holding a lab report. Under the 2025 guideline, the decision to start medication no longer rests on your blood pressure reading alone. It runs through a risk score, and that score is fed by blood and urine test results.
What the July 29 analysis found
Researchers at Keele University and the University of Manchester applied the 2025 American Heart Association and American College of Cardiology recommendations to national survey data. Of the 81 million US adults with a diagnosis of उच्च रक्तचाप, 22.8 million met the guideline threshold for medication based on a reading of 130/80 mm Hg or higher. Of those, 13.1 million were already treated and 9.7 million were not. Among eligible adults, receiving medication was associated with a 23% lower risk of dying from any cause and a 50% lower risk of dying from a heart-related cause. If treatment were extended to everyone eligible and untreated, the authors estimate roughly 200,000 deaths from any cause and 162,000 cardiovascular deaths could be avoided over the next decade. The adults who stood to benefit most were older, average age 66, and carried more diabetes and chronic kidney disease. One limitation is worth stating plainly: blood pressure was measured at a single survey visit, whereas the guideline itself asks for multiple readings on multiple occasions.
Why your blood pressure number is no longer the whole decision
The 2025 guideline keeps lifestyle change as the foundation and adds a second step for adults aged 30 to 79 without established cardiovascular disease: estimate 10-year and 30-year risk using the American Heart Association’s PREVENT equations. The practical consequence is that two people with identical readings can receive different advice, because the score also weighs what is happening in the blood and the kidneys. The threshold quoted by the study’s senior author is concrete. Someone with a reading under 140/90 mm Hg, no history of heart disease, stroke, chronic kidney disease or diabetes, and a PREVENT 10-year risk under 7.5% can reasonably start with lifestyle alone. Above that, medication enters the conversation. None of it can be calculated without laboratory values.
The lab values that feed the score
PREVENT was designed around inputs a primary care office already has. Three of them come from a blood draw and are not optional: कुल कोलेस्ट्रॉल (Total Cholesterol), एचडीएल कोलेस्ट्रॉल, और ईईजीएफआर, the estimated filtration rate derived from your क्रिएटिनिन. Adding kidney function is precisely what distinguishes PREVENT from the older equations it replaced. Two further tests are optional and refine the estimate: एचबीए 1 सी and the urine एल्बुमिन-टू-क्रिएटिनिन रेशियो (Albumin-to-Creatinine Ratio).
| Value | Where it appears on your report | Role in the decision |
|---|---|---|
| कुल कोलेस्ट्रॉल | लिपिड पैनल | Required input to the risk score |
| एचडीएल कोलेस्ट्रॉल | लिपिड पैनल | Required input to the risk score |
| eGFR (from creatinine) | Metabolic or kidney panel | Required input; the kidney measure PREVENT added |
| एचबीए 1 सी | Ordered separately in most panels | Optional; sharpens the estimate, especially with diabetes |
| यूरिन एल्बुमिन-टू-क्रिएटिनिन रेशियो (Urine Albumin-to-Creatinine Ratio) | Urine test, ordered by name | Optional; the most frequently skipped input |
| Potassium and creatinine | Metabolic panel | Not risk inputs; baseline and safety follow-up once treatment starts |
If your most recent report has no lipid line and no filtration rate, the score behind your treatment plan was estimated on incomplete information. That is a reasonable thing to raise at your next appointment.
हाल के विज्ञान से आपके लिए क्या बदलता है
Four findings turn this into something you can act on. First, a 2024 analysis in JAMA modeled what happens when the PREVENT equations replace the older pooled cohort equations on the same population: about half of US adults shift into a lower risk category, and very few move higher. Same person, same blood pressure, a different calculator, a different recommendation. That is not a reason to distrust the score, but it is a reason to know which one was used and on what inputs.
Second, the optional test is the one that gets skipped. A Danish study followed 144,644 patients starting blood pressure medication and found that 80% had never had their urine albumin-to-creatinine ratio measured at the time treatment began. Among those who had, the ones with high albumin levels carried roughly double the two-year risk of a major cardiovascular event and a markedly higher risk of losing kidney function. Third, a 2025 cohort analysis went further and found that even values sitting inside the conventionally normal range, between 10 and 30 mg/g, were associated with higher mortality in people with hypertension. A 2025 review in Circulation makes the case for treating this ratio as a single unifying marker across heart, kidney and metabolic health rather than a kidney-only afterthought. The practical translation is short: ask for the urine albumin-to-creatinine ratio by name, and do not read a low-but-not-zero result as nothing.
Fourth, once medication starts, two familiar values become safety instruments rather than risk inputs. Current guidance is to recheck पोटेशियम and creatinine after beginning an ACE inhibitor or an angiotensin receptor blocker, and a 2025 study in the Journal of Hypertension built prediction models to identify who needs closer watching. The reassuring counterpart comes from a 2026 primary care cohort of 9,926 patients, where high potassium occurred in 1.8% and a creatinine rise of 30% or more in 2.5%. Uncommon, but exactly the reason the follow-up draw exists. Ask when it is scheduled rather than waiting to be called.
Reading your own report before the appointment
Three checks cover most of it. Look for a lipid line and a filtration rate; those two carry the score. Look for an albumin-to-creatinine ratio or a माइक्रोएल्ब्यूमिन्यूरिया result, and if there is none, that is the test to request. And treat a single abnormal creatinine with some caution, since filtration estimates can be thrown off by muscle mass and by hydration, which is one reason cystatin C is increasingly used alongside creatinine and why dehydration can distort both your reading and your labs. The same logic applies to the lipid side, where the number on your report is often calculated rather than measured.
शब्दकोष
- PREVENT equations: a risk calculator from the American Heart Association that estimates the chance of a cardiovascular event over 10 and 30 years, using blood pressure, cholesterol and kidney measures.
- eGFR: estimated glomerular filtration rate, a calculation based on creatinine that summarizes how well the kidneys filter.
- Urine albumin-to-creatinine ratio: a urine test that detects small amounts of albumin leaking into urine, an early sign of vessel and kidney strain.
- Primary prevention: treatment given to someone who has not yet had a heart attack or stroke, to prevent a first one.
- Hyperkalemia: a potassium level above the reference range, which some blood pressure medications can cause.
अक्सर पूछे जाने वाले प्रश्नों
Do I need blood tests before starting blood pressure medication?
In practice yes. The 2025 guideline asks for a risk estimate that requires total cholesterol, HDL cholesterol and a filtration rate derived from creatinine. A potassium and creatinine baseline is also standard before starting most medications, so the same draw usually covers both purposes.
What is a PREVENT score under 7.5%?
It means an estimated risk of a cardiovascular event over the next 10 years below 7.5 in 100. For someone with a reading under 140/90 mm Hg and no heart, kidney or diabetes history, that generally supports starting with lifestyle change rather than medication. The number is a starting point for a conversation, not a verdict.
Is the urine albumin-to-creatinine ratio part of routine bloodwork?
No. It is a urine test and it has to be ordered specifically. Danish data show four out of five patients starting blood pressure treatment had never had it done, even though results outside the normal range point to meaningfully higher cardiovascular and kidney risk.
My blood pressure is 132/84. Does that mean medication?
Not by itself. That reading sits in the range where the guideline asks for a risk estimate and for repeated measurements on separate occasions before deciding. What tips the balance is the combination of the reading, the risk score built from your labs, and your history.
सूत्रों का कहना है
- American Heart Association. Independent study: nearly 1 in 3 US adults with high blood pressure may need medication. July 29, 2026. newsroom.heart.org
- Al-Jarshawi M, Mamas MA, et al. Population-Level 10-Year Implications of the New 2025 AHA/ACC Hypertension Guideline Recommendations for Primary Prevention in the United States: A NHANES-Based Cohort Study (2009-2018). Journal of the American Heart Association, 2026. DOI 10.1161/JAHA.125.048616. Coverage and study summary
- American Heart Association. 2025 Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. professional.heart.org
- American Heart Association. PREVENT risk calculator. professional.heart.org
- National Heart, Lung, and Blood Institute. High Blood Pressure. nhlbi.nih.gov
- National Kidney Foundation. Albuminuria. kidney.org
- Diao JA, Shi I, Murthy VL, et al. Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations. JAMA, 2024. consensus.app
- Binding C, et al. Urinary albumin-to-creatinine ratio in patients with hypertension and risk of major cardiovascular events. Open Heart, 2025. consensus.app
- Wang D, et al. Urinary Albumin-to-Creatinine Ratio, Cardiovascular Health, and All-Cause Mortality in Hypertension: A Nationwide Cohort Analysis. The Journal of Clinical Hypertension, 2025. consensus.app
- Claudel SE, et al. Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review. Circulation, 2025. consensus.app
- Wang A, et al. Developing prediction models for electrolyte abnormalities in patients indicated for antihypertensive therapy. Journal of Hypertension, 2025. consensus.app
- Lim M, et al. Incidence of hyperkalaemia and major creatinine elevation after renin-angiotensin system inhibitor initiation in a Singapore primary care cohort. BMC Primary Care, 2026. consensus.app
अग्रिम पठन
- High blood pressure: symptoms, numbers and how to lower it
- किडनी फंक्शन पैनल (Kidney Function Panel) को समझें
- What a lipid panel actually measures
- Lipoprotein(a): the cholesterol test now recommended once for every adult
- What a comprehensive blood panel covers
AI DiagMe के साथ अपनी रिपोर्ट को समझें
A blood pressure decision is now a reading plus a handful of laboratory values, and those values only make sense together. AI DiagMe helps you see what your cholesterol, kidney and glucose markers say as a whole, spot which line is missing from your report, and arrive at your next appointment with the right question rather than a list of numbers. The tool helps you understand your results; it does not diagnose and does not replace your doctor. कुछ ही मिनटों में अपनी रिपोर्ट समझें.
